Oncologix Tech Stock Probability of Future Pink Sheet Price Finishing Over 8.8E-5
Oncologix Tech's future price is the expected price of Oncologix Tech instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Oncologix Tech performance during a given time horizon utilizing its historical volatility. Check out Oncologix Tech Backtesting, Oncologix Tech Valuation, Oncologix Tech Correlation, Oncologix Tech Hype Analysis, Oncologix Tech Volatility, Oncologix Tech History as well as Oncologix Tech Performance.
Please specify Oncologix Tech's target price for which you would like Oncologix Tech odds to be computed.
Oncologix |
Oncologix Tech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncologix Tech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncologix Tech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oncologix Tech generated a negative expected return over the last 90 days | |
| Oncologix Tech has high historical volatility and very poor performance | |
| Oncologix Tech has some characteristics of a very speculative penny stock | |
| Oncologix Tech has a very high chance of going through financial distress in the upcoming years | |
| Oncologix Tech currently holds 3.97 M in liabilities. Oncologix Tech has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncologix Tech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncologix Tech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncologix Tech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncologix to invest in growth at high rates of return. When we think about Oncologix Tech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.85 M. Net Loss for the year was (2.37 M) with profit before overhead, payroll, taxes, and interest of 614.41 K. | |
| Oncologix Tech currently holds about 86.31 K in cash with (24.2 K) of positive cash flow from operations. |
Oncologix Tech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncologix Pink Sheet often depends not only on the future outlook of the current and potential Oncologix Tech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncologix Tech's indicators that are reflective of the short sentiment are summarized in the table below.
| Short Long Term Debt | 5.2 M | |
| Shares Float | 736.6 M |
Oncologix Tech Technical Analysis
Oncologix Tech's future price can be derived by breaking down and analyzing its technical indicators over time. Oncologix Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Oncologix Tech. In general, you should focus on analyzing Oncologix Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Oncologix Tech Predictive Forecast Models
Oncologix Tech's time-series forecasting models is one of many Oncologix Tech's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Oncologix Tech's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Oncologix Tech
Checking the ongoing alerts about Oncologix Tech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Oncologix Tech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Oncologix Tech generated a negative expected return over the last 90 days | |
| Oncologix Tech has high historical volatility and very poor performance | |
| Oncologix Tech has some characteristics of a very speculative penny stock | |
| Oncologix Tech has a very high chance of going through financial distress in the upcoming years | |
| Oncologix Tech currently holds 3.97 M in liabilities. Oncologix Tech has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncologix Tech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncologix Tech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncologix Tech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncologix to invest in growth at high rates of return. When we think about Oncologix Tech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 2.85 M. Net Loss for the year was (2.37 M) with profit before overhead, payroll, taxes, and interest of 614.41 K. | |
| Oncologix Tech currently holds about 86.31 K in cash with (24.2 K) of positive cash flow from operations. |
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.